RPRX Price Prediction Next Week
Technical Analysis Based on recent price action, RPRX shows strong bullish momentum with RSI at 78.16 indicating overbought conditions. The stock is trading above all major moving averages (5,10,20,60,200-day SMAs), suggesting a robust uptrend.
Price Targets for Next Week
- Support levels: $31.59 (Fibonacci S1), $31.02 (Fibonacci S2)
- Resistance levels: $33.41 (Fibonacci R1), $33.98 (Fibonacci R2)
News Impact Recent positive catalysts include:
- Ex-dividend date on 2/21/25 with $0.22 quarterly dividend
- Strategic R&D funding agreement with Biogen worth up to $250 million for lupus treatment development
Price Prediction Based on technical indicators and recent news:
- Short-term target: $34.00 (Fibonacci R2 level)
- The stock is likely to experience a minor pullback early in the week due to overbought conditions before continuing its upward trend
- Expected trading range: $31.59 - $34.00
Recommendation HOLD/SELL. While the long-term outlook remains positive, current overbought conditions and proximity to resistance levels suggest taking profits or reducing positions at current levels. Better entry points may present themselves after a healthy pullback to support levels.
RPRX Similar Chart Price Prediction
The price of RPRX is predicted to go up 0.35%, based on the high correlation periods with INGR. The similarity of these two price pattern on the periods is 96.74%.
RPRX
INGR
Up: 0.35%Similarity: 96.74%
RPRX Revenue Forecast
RPRX EPS Forecast
RPRX FAQs
What is bull’s view on RPRX?
What is bear's view on RPRX?
What is RPRX revenue forecast for next quarter？
What is RPRX eps forecast for next quarter？
RPRX VS S&P500
Royalty Pharma's portfolio includes market-leading therapies for a wide range of diseases, enabling stable future royalty streams and high returns on investments over the next decade.
Demand for increased funding across the biopharma ecosystem for new product development expands Royalty Pharma's potential addressable market.
Royalty Pharma's capacity to execute large deals and connections with royalty holders make the company a preferred choice for royalty transactions.
RPRX Analyst's Forecast
Andrew Baum
Citigroup
Strong Buy
2024-10-25
Price Target
$60 → $40
Upside
+48.42%
Citi lowered the firm's price target on Royalty Pharma to $40 from $60 and keeps a Buy rating on the shares following a transfer of coverage. Royalties from Vertex's portfolio of assets in cystic fibrosis have been a significant contributor for Royalty Pharma since acquiring royalty rights from the cystic fibrosis Foundation ten years ago, the analyst tells investors in a research note. The firm says new data or launches could drive demand and a "growth step" for the company.
